Last checked at 18 Apr 2019 15:40
18 April 2019 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchases by Directors
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:
Name | Title | Number of Ordinary Shares purchased | Total beneficial interest in the Company's Ordinary Shares | Percentage of Company's Total Voting Rights |
Professor Sir Chris Evans OBE | Non-executive Director | 10,000 | 254,605 | 0.802 |
ENDS
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer
| |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Tilly Abraham
| |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
| |
Nplus1 Singer Advisory LLP | +44 (0) 20 7496 3000 |
Aubrey Powell, Mark Taylor (Joint Broker) |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
Notification and public disclosure of transactions by persons discharging managerial
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Professor Sir Chris Evans OBE | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | 2138003TU12CQ5TZO137 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00BF5G6K95 | ||||
b) | Nature of the transaction | Purchase of ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | 18 April 2019 | ||||
f) | Place of the transaction | London Stock Exchange AIM Market | ||||